secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2021-09-02T23:59:59+00:00
Accession:  0001178913-21-002894
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab appoints Dale Pfost as CEO; co-founder Adi Mor becomes CSO
-------------------------------------------------------------------

- Dr. Dale Pfost appointed CEO, subject to shareholder approval expected Q4 2021.
- Dr. Adi Mor steps down as CEO, continues as Chief Scientific Officer and board member.
- Pfost brings 35 yrs experience; served as CEO of six biotech firms, including public companies.
- Pfost expected to join board and become Chairman in 2022 (subject to shareholder approval).
- Company has two Phase 2 studies underway; third expected to start in coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321002894/0001178913-21-002894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321002894/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-21-002894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer